BCAN's Patient Handbook - Bladder Cancer Basics for the Newly Diagnosed



Donate Now to Support the Bladder Cancer Advocacy Network



Join The Online Bladder Cancer Support Community



The Bladder Cancer Advocacy Network (BCAN) is proud to announce that we have been designated a Marine Corps Marathon (MCM) Charity Partner! BCAN has been allocated 25 guaranteed entries for the 38th Annual Marine Corps Marathon to be held on October 27, 2013; an event that sold out in 2 hours and 41 minutes in 2012.
  • We are looking at building “Team BCAN” to not only run in the event and raise awareness for bladder cancer but to raise needed funds for fostering research and patient education. According to the Marine Corps Marathon, there is not a required qualifying time to participate in the event, but all runners should maintain at least a 14 minute mile pace. In order to become a member of “Team BCAN” and officially have a slot in this year’s race, you must be registered through BCAN.
  • No federal or Marine Corps endorsement is implied.
  • If you are interested in becoming a member of BCAN’s team or have any questions, please contact Larry Rzepka, BCAN’s Executive Director, at lrzepka@bcan.org.
  • abshipley.jpg
    William U. Shipley, M.D., FACR
    Professor of Radiation Oncology
    Harvard Medical School and Massachusetts General Hospital
    William U. Shipley, M.D., FACR, completed his medical degree at Harvard Medical School in 1966. After internship and 2 years of surgical residency at the Massachusetts Genera Hospital, he trained in Radiation Oncology at the Harvard Joint Center and then was in London for one year on the HMS Moseley Fellowship. He currently is the Andres Soriano Professor of Radiation Oncology at the Harvard Medical School and the Head of Genito-Urinary Oncology in the Department of Radiation Oncology at the Massachusetts General Hospital.

    After joining the staff at Massachusetts General Hospital in 1974, Dr. Shipley became a leader in clinical research in the area of genitourinary oncology evaluating multi-modality cancer care. He entered into a very special cooperation with his MGH colleagues in urology, in medical oncology, in radiation oncology and in pathology resulting in the implementation of seven successive national protocols for muscle-invading bladder cancer patients using a multi-modality approach which allowed over two thirds of those patients so-treated to escape without receiving radical bladder-removing surgery.

    In prostate cancer Professor Shipley helped develop and lead 10 randomized clinical trials using radiation therapy evaluating the advantages of high dose proton beam irradiation and evaluating in the National Radiation Group, the RTOG, the benefits of combining androgen deprivation with radiation in men with localized prostatic cancer.

    Professor Shipley, who holds many national and international leadership positions on committees and consensus panels in genitourinary oncology, has also chaired the American Society for Radiation Therapy and Oncology committee that has developed International educational courses with the local radiation oncology societies of emerging countries.

    Click here for more information.